drugset / Trial / NCT00131274

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

NCT00131274

Phase 2/3 Completed 120 enrolled Daniels, Craig E., M.D. Novartis · collab
RandomizedParallel-groupDouble-blindEct

Summary

The purpose of the study is to evaluate the safety and efficacy of Gleevec (imatinib mesylate) in the treatment of idiopathic pulmonary fibrosis (IPF).

Timeline

Start
2003-04
Primary completion
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 600 mg Oral